IL-10 Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4+ T Cell Migration

Collin-Jamal Smith, Denise E. Allard, Yan Wang, James F. Howard Jr., Stephanie A. Montgomery and Maureen A. Su
J Immunol March 1, 2018, 200 (5) 1580-1592; DOI: https://doi.org/10.4049/jimmunol.1701280

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a debilitating condition caused by autoimmune demyelination of peripheral nerves. CIDP is associated with increased IL-10, a cytokine with well-described anti-inflammatory effects. However, the role of IL-10 in CIDP is unclear. In this study, we demonstrate that IL-10 paradoxically exacerbates autoimmunity against peripheral nerves. In IL-10–deficient mice, protection from neuropathy was associated with an accrual of highly activated CD4+ T cells in draining lymph nodes and absence of infiltrating immune cells in peripheral nerves. Accumulated CD4+ T cells in draining lymph nodes of IL-10–deficient mice expressed lower sphingosine-1-phosphate receptor 1 (S1pr1), a protein important in lymphocyte egress. Additionally, IL-10 stimulation in vitro induced S1pr1 expression in lymph node cells in a STAT3-dependent manner. Together, these results delineate a novel mechanism in which IL-10–induced STAT3 increases S1pr1 expression and CD4+ T cell migration to accelerate T cell–mediated destruction of peripheral nerves.

This article is featured in In This Issue, p.1531

Introduction

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common acquired autoimmune peripheral neuropathy, affecting as many as 9 in 100,000 people (1). Sometimes considered the chronic form of Guillain-Barré Syndrome, CIDP is characterized by relapsing-remitting or progressive sensory dysfunction, paresthesia, and weakness due to autoimmune demyelination of nerves in the peripheral nervous system (PNS) (2). First-line treatment options include glucocorticoids, i.v. Ig, and plasma exchange, which use nonspecific mechanisms of action against CIDP, do not improve disease symptoms in one third of patients, and do not achieve remission or cure in over 70% of patients (3, 4). Thus, current treatments fail to address considerable CIDP disease burden. Better understanding of CIDP pathogenesis is an important step toward developing new mechanism-based therapies with greater efficacy.

Substantial evidence suggests T cells are critical for the development of CIDP (1). First, NOD mice develop spontaneous autoimmune peripheral polyneuropathy (SAPP) that resembles CIDP due to defective negative selection of T cells (5, 6). Second, T cell–deficient mice fail to develop experimental autoimmune neuritis, which is an induced model of CIDP (7). Third, CD4+ T cells are sufficient to transfer SAPP (5, 6, 8). Finally, T cells are present in sural nerve infiltrates of CIDP patients (1).

A key function of T cells is the secretion of cytokines (1, 9), and CIDP has been associated with increased IFN-γ (10, 11), and TNF-α (12). Blockade of IFN-γ and TNF-α in SAPP mouse models have revealed disease-promoting roles for these cytokines (13–15). Interestingly, increased IL-10 expression has also been associated with CIDP (10, 16). However, the role of IL-10 in CIDP pathogenesis is unclear.

IL-10 has multiple anti-inflammatory effects, which include suppressing production of proinflammatory cytokines, chemokines, and costimulatory molecules in macrophages and dendritic cells (17, 18). IL-10 dampens autoimmunity in multiple disease models, including rheumatoid arthritis (RA) (19, 20) and multiple sclerosis (MS) (21, 22). Although IL-10 typically suppresses inflammation, it has also been reported to promote immune responses. For example, IL-10 secretion by Th2 cells promotes differentiation and Ab secretion in B cells (23, 24), which is strongly associated with inflammation in systemic lupus erythematosus (25) and allergy (26). Furthermore, IL-10 stimulates the expansion and differentiation of effector CD8+ T cells, which boosts antitumor immunity in mice (27). Thus, although IL-10 is most commonly regarded as an anti-inflammatory cytokine, it is a pleiotropic cytokine that can also promote inflammation in certain immune contexts.

IL-10 binding to IL-10 receptor 1 leads to phosphorylation of STAT3 (18). Along with increased IL-10, CD4+ T cells from CIDP patients with active disease have higher pSTAT3 (10). Separately, pSTAT3 has been shown to induce sphingosine-1-phosphate receptor 1 (S1PR1) expression (28). S1PR1 is essential for lymphocyte egress from lymph nodes (29), and has been implicated in SAPP pathogenesis (30). The concurrent roles of pSTAT3 in IL-10 signaling and S1PR1 transcriptional induction suggest that IL-10 may contribute to S1PR1 expression and S1PR1-dependent lymphocyte migration. However, multiple cytokines can activate STAT3, and it is unclear whether IL-10–induced pSTAT3 upregulates S1PR1 expression.

In this study, we found that, like CIDP patients, mice with SAPP have robust induction of IL-10. IL-10 expression was increased in inflamed peripheral nerves and T cells isolated from spleens and lymph nodes. Unexpectedly, IL-10–deficient mice were protected from neuropathy development, suggesting IL-10 is a pathogenic cytokine in SAPP. IL-10 deficiency was associated with accumulation of activated CD4+ T cells in the draining lymph nodes and decreased PNS infiltration. These findings suggested that impaired T cell egress may underlie SAPP protection in IL-10 deficiency. Indeed, IL-10–deficient CD4+ T cells lacked S1pr1 expression and displayed reduced migration to the S1PR1 ligand sphingosine-1-phosphate (S1P). Moreover, IL-10 induced S1PR1 mRNA expression, and IL-10–mediated S1pr1 expression required STAT3. Together, these findings illustrate a previously unappreciated role of IL-10 in promoting S1PR1-dependent lymphocyte migration and autoimmune destruction of peripheral nerves.

Materials and Methods

Mice

A strain of NOD mice that develops SAPP due to a dominant-negative G228W mutation in the autoimmune regulator gene (NOD.AireGW/+) mice were generated as previously described (31). NOD.Scid (JAX stock #001303), NOD.μMT−/− (JAX stock #004639), and NOD.Il10−/− (JAX stock #004266) mice were purchased from the Jackson Laboratory. Mice were housed in a specific pathogen-free barrier facility at the University of North Carolina, Chapel Hill. Clinical neuropathy, determined by hind limb weakness, and diabetes, determined by presence of glucose in urine, were assessed at least once per week as described previously (8). Diabetic mice were treated daily with i.p. insulin until used in experiments or euthanasia (due to >20% weight loss). Only female mice were used due to higher SAPP incidence relative to males (5). Mice were used at 22 wk of age unless otherwise noted. Due to the rapid progression of disease and death following initial symptoms, mice that developed SAPP prior to 22 wk of age were harvested at SAPP onset. NOD.AireGW/+ Il10+/− or NOD.AireGW/+ Il10−/− mice were used as splenocyte donors. Experiments complied with the Animal Welfare Act and the National Institutes of Health guidelines for the ethical care and use of animals in biomedical research.

Immunohistochemistry

Mouse sciatic nerves were embedded in OCT compound, frozen at −20°C for 2 h, and then stored at −80°C. Longitudinal 6 μm-thick sections were fixed with cold acetone, blocked with 2.5% goat serum, and then stained with anti–IL-10 Ab (clone JES5-16E3; BioLegend) for 2 h at room temperature. After washing with PBS + 0.1% Tween, sections were incubated with anti–rat-HRP Ab for 30 min at room temperature. DAB solution (Vector Laboratories) was applied to the sections as the chromogen. Brightness of all images was increased by 10 in Adobe Photoshop.

Flow cytometry

Flow cytometry was performed as previously described (32). Briefly, single-cell suspensions were isolated from spleens or lymph nodes by crushing with forceps, or from sciatic nerves by mincing and digestion in 2 mg/ml collagenase. Cells were stained with live/dead fixable yellow dye (Life Technologies), anti-mouse CD4 (clone GK1.5; BioLegend), anti-mouse CD44 (clone IM7; eBioscience), anti-mouse CD62L (clone MEL-14; eBioscience), anti-mouse S1PR1 (clone 713412; R&D), anti-mouse IFN-γ (clone XMG1.2; eBioscience), and anti-mouse IL-10 (clone JES5-16E3; BD) Abs. For intracellular cytokine staining, cells were stimulated with PMA/ionomycin for 4 h at 37°C 5% CO2, and permeabilized using BD Cytofix/Cytoperm according to the manufacturer’s instructions. Cells were analyzed on a CyAn ADP Analyzer (Beckman Coulter). Data were analyzed using FlowJo ×.

Histology

Harvested organs were fixed in 10% buffered formalin for at least 96 h, washed in 30% ethanol for 20 min, and then stored in 70% ethanol. Organs were embedded in paraffin, sectioned, and stained with H&E by the University of North Carolina Animal Histopathology Core. Immune infiltration was scored while blinded to genotype as previously described (31). For sciatic nerves, scores of 0, 1, 2, 3, and 4 indicate 0, 1–25, 26–50, 51–75, and >75% infiltration, respectively. Colon histology was scored in a blinded fashion by a board-certified veterinary pathologist as previously described (33). Briefly, H&E-stained distal colonic sections were scored based on an additive histological injury system that included mucosal ulceration, epithelial hyperplasia, and lamina propria mononuclear and neutrophil infiltrates. Pancreatic islet infiltration was scored in a blinded fashion as previously described (34). Briefly, H&E-stained pancreatic sections were scored based on average degree of islet infiltration. Brightness of all images was increased by 50 in Adobe Photoshop.

Electrophysiology

Sciatic nerve conduction studies were performed as described (35), using a Teca Synergy T2× EMG system.

Ab treatment

Anti–B7-1 Ab (clone 16.10A1) and anti–B7-2 Ab (clone GL1) were generous gifts of G. Szot (University of California, San Francisco) or purchased from Bio X Cell. To induce neuropathy, 14 d old NOD.Il10+/− or NOD.Il10−/− mice were treated with 50 μg Ab or isotype controls (2A3 and Armenian Hamster IgG) every other day for seven treatments (8, 15).

ELISPOT assay

ELISPOT assays were performed according to the manufacturer’s protocol (BD). In total, 1 million splenocytes or 8 × 105 lymph node cells were cultured alone, with synthetic OVA peptide (323–339) (InvivoGen), synthetic myelin protein zero (MPZ or P0) peptide (180–199) (Genemed Synthesis), or PMA/ionomycin in DMEM + 10% FBS for 17 h at 37°C 5% CO2. Spots were enumerated using the AID iSpot Reader.

Adoptive transfer

Adoptive transfer of CD4+ T cells from spleen was performed as previously described (5). Tissue culture plates were coated with 1 μg/ml anti-CD3ε (clone 145-2C11; eBioscience) and 1 μg/ml anti-CD28 (clone 37.51; BD Pharmingen) in sterile PBS overnight at 4°C. Plates were washed gently with sterile PBS. Whole spleens from 22 wk old NOD.AireGW/+ Il10+/− or NOD.AireGW/+ Il10−/− donors were cultured with plate-bound anti-mouse CD3 and anti-mouse CD28 in DMEM (Life Technologies) + 10% FBS (Sigma-Aldrich) for 4 d at 37°C 5% CO2. CD4+ T cells were purified from cultures using the Magnisort CD4+ T cell Enrichment Kit (Invitrogen) and 1 × 106 CD4+ T cells were transferred to NOD.Scid Il10+/− or NOD.Scid Il10−/− recipients. Diabetic mice were excluded as donors.

FTY720 treatment

AireGW/+ mice were treated with DMSO or 1 mg/kg FTY720 (Cayman Chemical). FTY720 was first dissolved in DMSO (25 g in 1 ml DMSO), aliquoted, and frozen at –20°C. Mice were given i.p. injections of DMSO or FTY720 dissolved 1:100 in 100 μl sterile water on every week day (5 d per wk) from 14 wk of age (before SAPP development) until utilization. Mice were harvested when they developed SAPP, or when all DMSO-treated controls developed SAPP.

Chemotaxis assay

Chemotaxis was measured using Transwell assays as described previously (36). Migration of lymph node cells was measured using a 24-well Transwell plate (Corning Life Sciences) with 6.5 mm polycarbonate filters and 5 μm pores. The lower chamber was coated overnight at 4°C with 600 μl of 100 μg/ml human collagen type IV (Sigma-Aldrich) in 0.5 M acetic acid, washed with PBS, and air dried. In total, 2 million cells were resuspended in 100 μl RPMI 1640 medium with 0.1% fatty acid-free BSA (Sigma-Aldrich), 100 U/ml penicillin G, 2 mM l-glutamine, and 25 mM HEPES buffer. Cells were placed on the Transwell inserts. S1P (20 nM in 600 μl) was added in the same medium to the lower chamber. Migration was performed for 4 h at 37°C 5% CO2. Migrated cells were counted with a hemocytometer. Migration assays without S1P were performed in parallel to assess baseline migration. Net migration to S1P was calculated by subtracting the number of cells that migrated nonspecifically from the number of cells that migrated to S1P.

IL-10 stimulation and real time RT-PCR

Briefly, 500,000 cells from fresh sciatic and lumbar lymph nodes of NOD.Il10−/− mice were stimulated with recombinant human IL-10 (100 ng/ml from PeproTech), stimulated with IL-10 and STA-21 (10 μM from Santa Cruz Biotech), or incubated without stimulation in XVIVO 15 + transferrin serum-free media (Lonza) for 30 min at 37°C 5% CO2. RNA was isolated from cells using the Zymo RNA MicroPrep kit. Superscript II (Invitrogen) reverse transcriptase was used to create cDNA. TaqMan universal PCR Master Mix (Applied Biosystems) was used for quantitative PCR (qPCR). Commercially available TaqMan primer-probe sets for IL-10 and S1Pr1 were used (Applied Biosystems). Cyclophilin A was used as an internal control and detected with the primer-probe set reported previously (31). Reactions were run on a Quantstudio 6 Flex system (Life Technologies) and analyzed as described (31).

Statistics

Data were analyzed with GraphPad Prism 6 using one-sample two-tailed Student t tests, unpaired two-tailed Student t tests, or one-way ANOVA. The Bonferroni or Tukey corrections for multiple comparisons were used when appropriate. Mantel–Cox log-rank tests were used to compare survival curves. R (v3.3.1) was used to perform Fisher exact test and false discovery rate adjustments. A p value < 0.05 was considered significant, unless the threshold was reduced for the Bonferroni correction.

Results

IL-10 promotes SAPP in two mouse models

IL-10 is increased in CIDP patients (10), but the functional significance of IL-10 in CIDP is unknown. To study this, we used a strain of NOD mice that develops SAPP due to a dominant-negative G228W mutation in the autoimmune regulator gene (NOD.AireGW/+; henceforth referred to as AireGW/+) (5). SAPP in AireGW/+ mice shares key features with CIDP, including infiltration of peripheral nerves by CD4+ T cells and F4/80+ macrophages (37–39), IFN-γ production by CD4+ T cells (10, 11), and demyelination of peripheral nerves (1, 5). Whether increased IL-10 expression is associated with SAPP in this model, however, is not known. IL-10 mRNA expression was compared by qPCR in whole sciatic nerve from NOD wild-type (WT) versus AireGW/+ mice with SAPP (Fig. 1A). IL-10 mRNA was not detected in WT nerves or young (<10 wk old) AireGW/+ nerves, whereas neuropathic (>15 wk old) AireGW/+ nerves expressed abundant IL-10. Additionally, immunohistochemical staining for IL-10 protein revealed increased protein expression in neuropathic AireGW/+ nerves compared with WT (Fig. 1B). Thus, similar to CIDP, SAPP in AireGW/+ mice is associated with increased IL-10 expression.

FIGURE 1.
FIGURE 1.

IL-10 deficiency is protective in SAPP. Relative IL-10 mRNA expression (A) and immunohistochemical stains of IL-10 (B) (original magnification ×200) in sciatic nerves of NOD.WT (WT) mice >15 wk old and NOD.AireGW/+ (AireGW/+) mice <10 wk old or >15 wk old. Scale bar, 100 μm. The p value was calculated using two-tailed unpaired Student t test with Welch correction. **p < 0.01. (C) Representative flow cytometry plots of splenic CD4+ T cells from IL-10–sufficient (IL-10+/−) and IL-10–deficient (IL-10−/−) AireGW/+ mice stained for intracellular IL-10. Gated on lymphocytes, singlets, and live cells. Numbers on plots represent frequencies of IL-10–expressing cells. WT Il10+/−, WT Il10−/−, AireGW/+ Il10+/−, and AireGW/+ Il10−/− mice were bred and monitored for SAPP. (D) SAPP incidence curves. Arrow points to age at which nerves were harvested for histology and EMG. The p value was calculated using Mantel–Cox log-rank test of AireGW/+ Il10+/− versus AireGW/+ Il10−/− mice. ***p < 0.001. (E) H&E-stained sciatic nerves from 22 wk old mice (original magnification ×200). Arrow points to areas of dense immune cell infiltration. Scale bar, 200 μm. (F) Cumulative sciatic nerve infiltration scores. The p values were calculated using Fisher exact test with Bonferroni correction. **p < 0.01. (G) Representative proximal and distal compound muscle action potentials from sciatic nerves of 22 wk old mice. Note that the y-axis (amplitude) scale is 20 mV in WT Il10+/− and AireGW/+ Il10−/− mice, but is reduced to 5 mV in AireGW/+ Il10+/− mice. (H) Cumulative peak amplitude, conduction velocity, and duration of compound muscle action potentials from 22 wk old mice. Each symbol represents an individual mouse. The p values were calculated using one-way ANOVA with Tukey correction for multiple comparisons. ***p < 0.001, ****p < 0.0001.

To determine IL-10’s role in SAPP pathogenesis, we crossed NOD.Il10−/− mice (40) with NOD.AireGW/+ mice to generate NOD.AireGW/+ Il10+/− and NOD.AireGW/+ Il10−/− mice. Lack of IL-10 protein expression in NOD.AireGW/+ Il10−/− mice was confirmed by intracellular IL-10 staining and flow cytometry of CD4+ T cells (Fig. 1C). On the C3H/HeJBir and 129/SvEv backgrounds, IL-10–deficient mice are susceptible to colitis, growth retardation, anemia, and early death (33, 41, 42). Such findings could potentially prevent our ability to observe SAPP in NOD.AireGW/+ mice. However, we did not observe colitis or its associated symptoms in NOD.WT Il10−/− or NOD.AireGW/+ Il10−/− mice (Supplemental Fig. 1, data not shown). These results are consistent with prior reports that colitis is mild and transient on the NOD background (43), and suggest that NOD.AireGW/+ Il10−/− mice can be used to understand the impact of IL-10 on SAPP development.

Given their utility, NOD.AireGW/+ Il10+/− mice and NOD.AireGW/+ Il10−/− littermates were monitored for SAPP for 30 wk. Consistent with our previous data, 80% of the IL-10–sufficient AireGW/+ mice developed SAPP by 22 wk of age (AireGW/+ Il10+/−, Fig. 1D) (5). Strikingly, compared with IL-10–sufficient AireGW/+ mice, IL-10–deficient AireGW/+ mice had a significant delay in SAPP (AireGW/+ Il10−/−, Fig. 1D), which suggests that IL-10 accelerates SAPP development. None of the IL-10–sufficient or deficient Aire WT mice developed SAPP during the study (WT Il10+/− or Il10-/–, Fig. 1D), indicating that IL-10 deficiency does not impair nerve function. Additionally, extensive cellular immune infiltrate was seen in H&E-stained sciatic nerves of IL-10–sufficient AireGW/+ mice, but was absent in IL-10–deficient AireGW/+ mice (Fig. 1E, 1F). Finally, SAPP in IL-10–sufficient AireGW/+ sciatic nerves was associated with electrophysiological changes consistent with demyelination, including prolonged distal motor latencies, slowed conduction velocity, and increased compound muscle action potential duration due to temporal dispersion relative to WT nerves (Fig. 1G, 1H). Conversely, abnormalities were not detected in sciatic nerves of IL-10–deficient AireGW/+ mice (Fig. 1G, 1H). IL-10 deficiency therefore protects against SAPP development, nerve infiltration, and electrophysiological changes in AireGW/+ mice. These findings that suggest that IL-10 promotes SAPP were surprising, given IL-10’s well-described functions as an immunoregulatory cytokine in a number of autoimmune diseases (17).

SAPP has been described in multiple mouse models, including NOD mice deficient in costimulatory molecules B7-1/2 (8). To determine whether the effect of IL-10 deficiency on SAPP was specific only to Aire-deficient mice or generalizable to other SAPP models, we treated IL-10–sufficient and IL-10–deficient WT mice with anti-mouse B7-1 and anti-mouse B7-2 to induce autoimmune peripheral neuropathy (8, 15). By ∼12 wk of age, 100% of the anti–B7-1/2 treated, IL-10–sufficient WT mice had SAPP compared with only 22% of IL-10–deficient WT mice (Fig. 2A). At 12 wk of age, sciatic nerves of IL-10–sufficient WT mice were heavily infiltrated, whereas sciatic nerves of IL-10–deficient WT mice had significantly less infiltration (Fig. 2B, 2C). These data suggest IL-10’s promotion of autoimmunity against peripheral nerves is not specific to the Aire-deficient model, but is a more generalizable feature of SAPP pathogenesis.

FIGURE 2.
FIGURE 2.

IL-10 deficiency is protective in anti–B7-1/anti–B7-2-induced autoimmune peripheral polyneuropathy. Anti–B7-1/anti–B7-2 or isotype-treated WT or WT Il10−/− mice were monitored for SAPP. (A) SAPP incidence curves. The p value was calculated using Mantel–Cox log-rank test of anti–B7-1/anti–B7-2– treated WT Il10+/– versus WT Il10−/− mice. **p < 0.01. Arrow points to age at which nerves were harvested for histology in (B and C). (B) H&E-stained sciatic nerves from 12 wk old mice (original magnification ×200). Arrows point to areas of dense immune cell infiltration. Scale bar, 60 μm. (C) Cumulative sciatic nerve infiltration scores from 12 wk old mice. Each symbol represents an individual mouse. The p value was calculated using Fisher exact test;. *p < 0.05.

It is unclear whether IL-10’s effect in promoting SAPP reflects a more global, generalized role in promoting autoimmunity against all target tissues. In addition to SAPP, AireGW/+ mice also develop autoimmune diabetes (5), allowing us to concurrently assess the role of IL-10 in SAPP and diabetes in these mice. Although IL-10 deficiency delayed SAPP development, lack of IL-10 did not affect autoimmune diabetes development in AireGW/+ mice (Supplemental Fig. 2). This finding is consistent with previous reports that IL-10 does not alter diabetes incidence in NOD.WT mice (40). Thus, IL-10 appears to promote autoimmunity in a tissue-specific manner.

IL-10 produced by CD4+ T cells promotes SAPP development

Many cell types in the innate and adaptive immune systems produce IL-10 (18). Therefore, it is not clear which IL-10–producing cell type is important in promoting SAPP. A key source of IL-10 is CD4+ T cells, which are sufficient to transfer SAPP in multiple models (5, 6, 14). Given the critical role for CD4+ T cells in SAPP, we examined IL-10 expression in CD4+ T cells from WT and neuropathic AireGW/+ mice. IL-10 expression in CD4+ T cells from the spleen and nerve-draining lymph nodes of neuropathic AireGW/+ mice was significantly increased compared with WT mice (Fig. 3A, 3B). Furthermore, whereas CD4+ T cells were absent in WT sciatic nerves, >10% of infiltrating CD4+ T cells expressed IL-10 in AireGW/+ sciatic nerves. Thus, increased IL-10 expression within CD4+ T cells is associated with SAPP development.

FIGURE 3.
FIGURE 3.

IL-10 produced by CD4+ T cells promotes SAPP. Spleens, lumbar lymph nodes, and sciatic nerves of 22 wk old WT mice and AireGW/+ mice stained for intracellular IL-10. (A) Flow cytometry plots of CD4+ T cells. Gated on lymphocytes, singlets, and live cells. Numbers on plots represent frequencies of IL-10–expressing cells. (B) Cumulative frequencies of CD4+IL-10+ T cells. The p values were calculated using two-tailed unpaired Student t test with Welch correction. **p < 0.01, ***p < 0.001, ****p < 0.0001. (C) Schematic (left) and SAPP incidence curve (right) of NOD.Scid Il10+/− or NOD.Scid Il10−/− recipient mice receiving purified CD4+ T cells adoptively transferred from 22 wk old AireGW/+ Il10+/− or AireGW/+ Il10−/− donor mice. Arrow points to time when nerves were harvested for histology. The p values were calculated using Mantel–Cox log-rank test with false discovery rate adjustment for multiple comparisons. *p < 0.05. (D) H&E-stained sciatic nerves harvested 7 wk post-CD4+ T cell adoptive transfer from the groups described in (C) (original magnification ×200). Scale bar, 98 μm. (E) Cumulative infiltration scores of sciatic nerves from recipient mice 7 wk posttransfer. Grouped by donor genotype. The p value was calculated using Fisher exact test. **p < 0.01.

Given increased CD4+ T cell IL-10 expression with SAPP, we next sought to determine whether IL-10 production by CD4+ T cells is sufficient to promote SAPP. Purified AireGW/+ CD4+ T cells that were IL-10 sufficient or deficient were transferred to immunodeficient NOD.PrkdcScid/Scid (Scid) (44) recipients that were either IL-10 sufficient or deficient (outlined in Fig. 3C, left). IL-10–sufficient donor CD4+ T cells induced SAPP in IL-10–sufficient and deficient recipients 6–7 wk posttransfer (Fig. 3C, right). Conversely, IL-10–deficient donor CD4+ T cells induced SAPP in IL-10–sufficient and deficient recipients 10 wk posttransfer, which was a significant delay relative to IL-10–sufficient donors (Fig. 3C, right). At 7 wk posttransfer, recipients of IL-10–deficient donor CD4+ T cells displayed significantly less sciatic nerve infiltration than recipients of IL-10–sufficient donor CD4+ T cells (Fig. 3D, 3E). These data demonstrate that IL-10 production by CD4+ T cells promotes SAPP development.

IL-10 does not promote SAPP through its effects on B cells

IL-10 production by CD4+ Th2 cells can promote inflammation by enhancing B cell proliferation, differentiation, and Ab production (17, 23, 24). We therefore sought to test whether IL-10 promotion of SAPP development requires B cells. IL-10 sufficient AireGW/+ mice were crossed with NOD.μMT−/− mice that lack mature B cells (45), to generate AireGW/+ μMT+/− (B cell sufficient) and AireGW/+ μMT−/− (B cell deficient) progeny. Interestingly, SAPP occurred with the same incidence in B cell–sufficient and deficient AireGW/+ mice (Fig. 4A), suggesting that IL-10 does not promote SAPP through its effects on B cells. Furthermore, sciatic nerves from B cell–sufficient and deficient mice exhibited similar nerve conduction changes (Fig. 4B, 4C). Because B cells do not accelerate SAPP development, it is unlikely that B cell enhancement is the mechanism by which IL-10 promotes SAPP.

FIGURE 4.
FIGURE 4.

B cell deficiency does not protect from SAPP. WT μMT−/−, AireGW/+ μMT+/−, and AireGW/+ μMT−/− mice were monitored for SAPP. (A) SAPP incidence curve. The p value was calculated using Mantel–Cox log-rank test of AireGW/+ μMT+/− versus AireGW/+ μMT−/− mice; ns indicates no significant difference observed. (B) Representative proximal and distal compound muscle action potentials from sciatic nerves of 22 wk old mice. (C) Cumulative peak amplitude, conduction velocity, and duration of compound muscle action potentials of 22 wk old mice. The p value was calculated using one-way ANOVA with Tukey correction for multiple comparisons. Each symbol represents an individual mouse. ns, no significant difference observed.

IL-10–deficient AireGW/+ mice harbor highly activated CD4+ T cells

IL-10 has a well-described role in suppressing T cell activation (17). Because IL-10 unexpectedly promoted SAPP (Figs. 1, 2), whether IL-10 would suppress or enhance T cell activation was not clear. Thus, we characterized CD4+ T cell activation in IL-10–deficient AireGW/+ mice that were protected from SAPP. Frequencies of CD4+CD44hiCD62Llo activated T cells were compared in the spleens of WT, IL-10–sufficient AireGW/+, and IL-10–deficient AireGW/+ mice. IL-10–deficient AireGW/+ mice had significantly higher frequencies of activated CD4+ T cells relative to IL-10–sufficient WT mice and AireGW/+ mice (Fig. 5A, 5B). We next tested whether IL-10 would suppress or enhance CD4+ T cell expression of IFN-γ, a cytokine critical for SAPP development (14, 15). Whereas IL-10–deficient AireGW/+ mice had significantly greater frequencies and absolute numbers of IFN-γ–producing CD4+ T cells in the spleen compared with WT mice, numbers of IFN-γ–producing CD4+ T cells were not different compared with IL-10–sufficient AireGW/+ mice (Fig. 5C, 5D). In the draining lymph node, IL-10–deficient AireGW/+ mice had greater absolute numbers of IFN-γ–producing CD4+ T cells compared with both WT and IL-10–sufficient AireGW/+ mice (Fig. 5E, 5F). Thus, despite protecting from SAPP, IL-10 deficiency was associated with equivalent or increased CD4+ T cell activation and IFN-γ production.

FIGURE 5.
FIGURE 5.

CD4+ T cells in IL-10–deficient AireGW/+ mice are highly activated. CD4+ T cells from spleens and nerve-draining lymph nodes of 22 wk old WT, AireGW/+ Il10+/+ or +/−, and AireGW/+ Il10−/− mice were analyzed. (A) Flow cytometry plots of splenic CD4+ T cells stained for CD44 and CD62L. Gated on lymphocytes, singlets, live, CD4+ cells. Numbers on plots represent frequencies of CD44hiCD62Llo cells. (B) Cumulative frequencies of CD4+CD44hiCD62Llo activated T cells from spleens. The p values were calculated using one-way ANOVA with Tukey correction for multiple comparisons. ****p < 0.0001. (C) Flow cytometry plots of splenic CD4+ T cells stained for intracellular IFN-γ. Gated on lymphocytes, singlets, and live cells. Numbers on plots represent frequencies of IFN-γ–expressing cells. (D) Cumulative frequencies and numbers of CD4+IFN-γ+ T cells from spleens. The p values were calculated using one-way ANOVA with Tukey correction for multiple comparisons. *p < 0.05, **p < 0.01. (E) Flow cytometry plots of lymph node CD4+ T cells stained for intracellular IFN-γ. Gated on lymphocytes, singlets, and live cells. Numbers on plots represent frequencies of IFN-γ–expressing cells. (F) Cumulative frequencies and numbers of CD4+IFN-γ+ T cells from lymph nodes. The p values were calculated using one-way ANOVA with Tukey correction for multiple comparisons. *p < 0.05. (G) ELISPOT wells detecting IFN-γ from P0-stimulated splenocytes (original magnification ×43). (H) Cumulative numbers of IFN-γ spots from media only, OVA-stimulated, or P0-stimulated splenocytes. Horizontal bars represent medians. The p values were calculated using two-tailed, unpaired Student t test with Welch correction and Bonferroni correction. *p < 0.025, ***p < 0.001. (I) ELISPOT wells detecting IFN-γ from P0-stimulated lymph node cells (original magnification ×43). (J) Cumulative numbers of IFN-γ spots from P0-stimulated lymph node cells. Each symbol represents an individual mouse. The p values were calculated using two-tailed, unpaired Student t test with Welch correction and Bonferroni correction. *p < 0.025, **p < 0.01.

In addition to suppressing T cell activation, IL-10 also downregulates expansion of self-antigen specific T cells (46). Because IL-10 unexpectedly promoted SAPP, however, we sought to determine how IL-10 deficiency would alter the precursor frequency of PNS-specific T cells. Pathogenic CD4+ T cells target the self-antigen P0 (5). For this reason, we assessed the expansion of P0-specific CD4+ T cells using an ELISPOT detecting IFN-γ. Briefly, 1 million splenocytes from WT, IL-10–sufficient AireGW/+, and IL-10–deficient AireGW/+ mice were left unstimulated (media), stimulated with MHC class II–restricted OVA irrelevant peptide, stimulated with MHC class II–restricted P0 peptide, or stimulated with PMA/ionomycin for a positive control (data not shown). IL-10–deficient AireGW/+ splenocytes stimulated with P0 elicited a median of 94 IFN-γ spots, which was significantly higher than WT (11 spots) and similar to IL-10–sufficient AireGW/+ mice (93 spots) (Fig. 5G, 5H). We also tested cells from the nerve-draining lymph nodes for response to P0. Similar to spleen, the number of P0-specific T cells was significantly higher in IL-10–deficient AireGW/+ lymph nodes (99 spots) relative to WT (six spots) and similar to IL-10–sufficient AireGW/+ mice (111 spots) (Fig. 5I, 5J). Thus, IL-10 deficiency protected from the development of SAPP, but does not decrease the frequency of nerve-specific CD4+ T cells in spleen or draining lymph nodes.

IL-10 deficiency is associated with enlarged lumbar lymph nodes, impaired lymphocyte migration, and reduced S1pr1 expression in CD4+ T cells

IL-10 deficiency was associated with minimal immune infiltrate in the sciatic nerves (Figs. 1, 2) and, concurrently, activated T cells in the spleen and lymph nodes (Fig. 5). One potential explanation for these disparate findings is that IL-10 is required for T cell egress from secondary lymphoid structures. Without IL-10, then, activated T cells may accumulate in the lymph nodes rather than migrating into peripheral nerves. Because reduced lymphocyte egress is associated with increased lymph node cellularity (47), we first tested whether IL-10 deficiency may affect migration by investigating lymph node size in IL-10–deficient mice. Indeed, the nerve-draining lumbar lymph nodes were enlarged in IL-10–deficient AireGW/+ mice relative to WT and IL-10–sufficient AireGW/+ mice (Fig. 6A). On average, IL-10–deficient AireGW/+ lumbar lymph nodes had >3-fold more cells than WT lymph nodes and ∼3-fold more cells than IL-10–sufficient AireGW/+ lymph nodes (Fig. 6B). These findings lend support to the hypothesis that IL-10 may accelerate SAPP by promoting migration of T cells out of lymph nodes and into nerves.

FIGURE 6.
FIGURE 6.

IL-10 promotes lymphocyte migration through STAT3-dependent S1pr1 induction. Image (A) and cumulative cell counts (B) of lumbar lymph nodes from 22 wk old WT, AireGW/+ Il10+/+ or +/–, and AireGW/+ Il10−/− mice. The p values were calculated using one-way ANOVA with Tukey correction for multiple comparisons. *p < 0.05. (C) Net migration in vitro to S1P of lymph node cells from 22 wk old AireGW/+ Il10+/+ or +/– and AireGW/+ Il10−/− mice. CD4+ T cells from lumbar lymph nodes of 22 wk old AireGW/+ Il10+/+ or +/– and AireGW/+ Il10−/− mice were analyzed for S1PR1 expression. The p value was calculated using two-tailed unpaired Student t test with Welch correction. **p < 0.01. (D) Relative S1pr1 mRNA expression. The p value was calculated using two-tailed unpaired Student t test with Welch correction. *p < 0.05. (E) Flow cytometry plots of lumbar lymph node CD4+ T cells stained for extracellular S1PR1. Gated on lymphocytes, singlets, and live cells. Numbers on plots represent frequencies of S1PR1-expressing cells. S1PR1 neg ctrl indicates negative control for S1PR1 staining. (F) Cumulative frequencies of CD4+S1PR1+ T cells. The p value was calculated using two-tailed unpaired Student t test with Welch correction. *p < 0.05. (G) Relative S1pr1 mRNA expression of lumbar lymph node cells from WT Il10−/− mice stimulated with recombinant IL-10 or IL-10 plus STAT3 inhibitor (STA-21). DMSO or FTY720-treated AireGW/+ mice were monitored for SAPP. The p values were calculated using one-sample t test (unstimulated versus IL-10) and two-tailed unpaired Student t test (IL-10 versus IL-10 + STA-21) with false discovery rate adjustment for multiple comparisons. *p < 0.05. (H) SAPP incidence curve. The p value was calculated using Mantel–Cox log-rank test. **p < 0.01. (I) H&E-stained sciatic nerves (original magnification ×200). Scale bar, 98 μm. (J) Cumulative sciatic nerve infiltration scores. The p value was calculated using Fisher exact test. *p < 0.05.

T cells exit lymph nodes by expressing S1PR1 on the cell surface and following gradients of S1P (29). To test IL-10’s effects on lymphocyte migration, we measured chemotaxis to S1P of lymph node cells from IL-10–sufficient and IL-10–deficient AireGW/+ mice in a Transwell assay. IL-10–deficient AireGW/+ lymph node cells had significantly reduced net migration to S1P, with a >3-fold reduction in migrating cells relative to IL-10–sufficient AireGW/+ mice (Fig. 6C). These findings suggest that IL-10 increases T cell migration to S1P.

We next sought to determine whether reduced chemotaxis to S1P by IL-10–deficient AireGW/+ lymphocytes may be due to reduced S1PR1 expression. To test this, we measured S1pr1 mRNA in CD4+ T cells purified from lumbar lymph nodes of IL-10–sufficient and deficient AireGW/+ mice. IL-10–deficient AireGW/+ CD4+ T cells expressed 12-fold lower levels of S1pr1 mRNA relative to IL-10–sufficient AireGW/+ controls (Fig. 6D). Conversely, IL-10 deficiency did not affect S1pr1 mRNA in lymph node CD4+ T cells of WT mice (Supplemental Fig. 3). To determine whether reduced S1pr1 mRNA correlated with reduced surface protein expression, we measured S1PR1 surface protein on CD4+ T cells from lumbar lymph nodes of IL-10–sufficient and deficient AireGW/+ mice. A significantly lower frequency of CD4+ T cells from lymph nodes of IL-10–deficient AireGW/+ mice expressed S1PR1 surface protein relative to IL-10–sufficient AireGW/+ mice (Fig. 6E, 6F). Thus, S1pr1 mRNA and protein were reduced in IL-10–deficient AireGW/+ CD4+ T cells. Together, these findings support a model in which IL-10 upregulates S1PR1 on CD4+ T cells to enhance their migration into the PNS and promote SAPP development.

IL-10 induces S1pr1 mRNA in a STAT3-dependent manner

How IL-10 upregulates S1pr1 expression is unclear. IL-10 signaling has been shown to activate STAT3, and, separately, STAT3 has been shown to upregulate S1PR1 transcription (17, 28). Based on these findings, we reasoned that IL-10 may induce S1pr1 in T cells via STAT3 activation. To test this, we stimulated lymph node cells with recombinant IL-10 in vitro and measured relative expression of S1pr1 by qPCR. Lymph node cells from IL-10–deficient (WT Il10−/−) mice were used to avoid preexisting induction of S1pr1 by IL-10. We stimulated whole lumbar lymph node instead of sorted CD4+ T cells because: 1) the lymph node is predominantly composed of T cells; and 2) the additional time required for sorting exposes the cells to an S1P-low environment, which may lead to S1pr1 resensitization (36, 48). IL-10 induced S1pr1 mRNA by ∼1.8-fold compared with unstimulated cells (Fig. 6G). Thus, addition of IL-10 is sufficient to upregulate S1pr1 in lymph node cells. Notably, STA-21, a STAT3 inhibitor (49), abrogated induction of S1pr1 by IL-10 (Fig. 6G). Together these data suggest that IL-10 activates STAT3 to induce S1pr1 transcription.

S1pr functional antagonist FTY720 suppresses SAPP development

S1PR1 expression was reduced in IL-10–deficient AireGW/+ mice (Fig. 6D–F), suggesting that decreased S1PR1 may underlie SAPP protection in IL-10–deficient AireGW/+ mice. S1PR1 blockade is being investigated for therapeutic potential in multiple autoimmune diseases (50), and is currently in clinical use for the treatment of MS (51), an autoimmune disease of the CNS. However, it is unclear whether loss of S1PR1 prevents SAPP development in AireGW/+ mice. To test this, we blocked S1PR1 activity in AireGW/+ mice using the S1PR functional antagonist FTY720 (52). FTY720-treated AireGW/+ mice were protected from SAPP development relative to DMSO-treated controls (Fig. 6H). Additionally, on H&E-stained sections of sciatic nerves, FTY720 treatment was associated with reduced infiltration (Fig. 6I, 6J). Thus, S1PR1 plays a key role in promoting SAPP and supports a model in which IL-10–mediated upregulation of S1PR1 promotes SAPP development.

Discussion

Similar to other autoimmune conditions, such as RA, Sjogren’s syndrome, and Grave’s disease (17, 53–55), IL-10 expression is upregulated in PBMCs of patients with autoimmune demyelinating polyneuropathy. Unlike most other autoimmune conditions, however, we report in this study that IL-10 promotes autoimmune peripheral neuropathy rather than suppressing the autoimmune response. Moreover, IL-10 deficiency was associated with an accumulation of activated CD4+ T cells in the draining lymph nodes and a lack of immune cell infiltration in nerves, which suggests a defect in lymphocyte egress from lymph nodes. Indeed, IL-10 deficiency was associated with reduced S1PR1-mediated lymphocyte migration, and IL-10 was sufficient to induce S1pr1 expression. These findings delineate a previously unappreciated mechanism by which IL-10 may function to promote autoimmune disease.

IL-10 has been reported to promote immune responses in other inflammatory contexts. For example, IL-10 enhances B cell–mediated immunity (23, 24). However, our data indicate that SAPP in Aire-deficient mice can occur independently of B cells. Thus, it is unlikely that IL-10 is functioning through B cell activation to promote SAPP. IL-10 also promotes CD8+ T cell–mediated immunity (27). Although it is possible that this IL-10–dependent mechanism may be contributing to SAPP development, our adoptive transfer experiments show that CD8+ T cells are dispensable for SAPP transfer because NOD.Scid mice lack CD8+ T cells (44). Instead, our data suggest IL-10 induces S1pr1 expression, which promotes CD4+ T cell–mediated migration from lymph nodes and autoimmunity against the PNS.

On the surface, our findings may seem to contradict a recent report that IL-10 protected NOD.B7-2−/− mice from SAPP (56). Quan et al. (56) show that transfer of dendritic cells pretreated with IL-10 protects from neuropathy. These seemingly contradictory results, however, may not be mutually exclusive. It is possible that IL-10 has distinct effects on different immune cell types in SAPP pathogenesis. Although IL-10 may have anti-inflammatory effects on dendritic cells, it may also promote CD4+ T cell egress from lymph nodes in SAPP. Overall, however, IL-10 appears to have a SAPP-accelerating effect, because mice with global IL-10 deficiency are protected from SAPP.

IL-10 protects against inflammation in multiple tissues, such as the colon, joints, and the CNS (17). What leads IL-10 to promote autoimmunity against the PNS, and not against other organs, is not clear. Peripheral nerves fundamentally differ from other tissues in several ways. For instance, a blood-nerve barrier surrounds the PNS, making it an immunologically privileged site (57). Furthermore, because nerve tissue and nerve Ags are widely dispersed throughout the body, the mechanisms behind nerve inflammation and tolerance may have unique characteristics. Also, tertiary lymphoid structures within target organs have been reported to be an important source of autoimmune T cells in autoimmune diabetes, MS, systemic lupus erythematosus, and RA (58), but are not seen in the PNS. Thus, differences in location (e.g., tertiary versus secondary) of critical lymphoid structures may be key in accounting for differences between organs.

CIDP has been observed in several patients with mutations in AIRE (59); however, the majority of CIDP patients have no known AIRE deficiency. Thus, an important question is whether results obtained in the Aire deficiency model of SAPP can be generalized. We observed that IL-10 deficiency protected mice from SAPP not only in the Aire deficiency (AireGW/+) model, but also in the Aire-independent, anti–B7-1/2 Ab-induced model. Thus, our findings suggest that IL-10’s promotion of SAPP pathogenesis is a common feature of autoimmune peripheral neuropathies. Because the Aire-deficient and anti–B7-1/2 Ab models are both on the NOD mouse background, it remains possible that IL-10’s promotion of PNS autoimmunity is specific to the NOD background. SAPP models reported to date are all on the NOD background (5, 6, 8, 60, 61), so it is not currently possible to test IL-10’s effects on SAPP in other mouse strains.

Given the efficacy of S1PR1 as a therapeutic target (50), there has been much effort in delineating factors controlling its expression. Although posttranscriptional and posttranslational regulation of S1PR1 have been well studied (48, 62–66), not as many transcriptional regulators have been found. Three known transcriptional regulators include vascular endothelial growth factor (67), Krüppel-like factor 2 (48, 68), and STAT3 (28). Lee et al. (28) found that STAT3-dependent induction of S1pr1 is partially driven by IL-6, because IL-6 signals through STAT3. In this study, we show a previously unappreciated function of IL-10 in inducing S1pr1 transcription through STAT3.

Our results have multiple clinical implications. We show that IL-10 paradoxically promotes SAPP, which suggests increased IL-10 observed in CIDP patients may be a marker of disease progression rather than resolution. Furthermore, IL-10 is under investigation to treat autoimmune and inflammatory diseases, including RA (19, 20), MS (21, 22), and Crohn’s disease (69). Our data suggest that IL-10 treatment may have previously unanticipated effects: IL-10 therapy may exacerbate disease in CIDP patients and/or unmask PNS autoimmunity in susceptible individuals. FTY720 is under investigation for clinical use to treat CIDP, and our data provide support for its use in treating autoimmune peripheral neuropathy (70). Separately, autoimmune peripheral neuropathies are an increasingly common side effect of current treatments and infections. For example, immune checkpoint inhibitors are being extensively tested in skin, lung, and kidney cancers, but may cause PNS autoimmunity (71, 72). Furthermore, recent Zika virus outbreaks have been strongly linked to an acute autoimmune peripheral neuritis that resembles Guillain-Barré syndrome (73, 74). Thus, there is mounting need to understand the pathogenesis of autoimmune peripheral neuropathies. This study demonstrates a critical role for IL-10 in promoting lymphocyte migration and accelerating PNS autoimmunity, and has far-reaching implications for current treatment strategies in cancer and autoimmunity.

Disclosures

The authors have no financial conflicts of interest.

Acknowledgments

We thank Edward Miao, Yisong Wan, Roland Tisch, Justin Wilson, Laurel Kartchner, and Hsing-Hui Wang for feedback on this manuscript. We thank Joshua Starmer and Dominic Moore for assistance with statistics. Animal histopathology was performed in the Lineberger Comprehensive Cancer Center Animal Histopathology Core Facility at the University of North Carolina at Chapel Hill. We thank the University of North Carolina at Chapel Hill Flow Cytometry core for assistance with flow cytometry experiments.

Footnotes

  • This work was supported by National Institutes of Health/National Institute for Neurological Disorders and Stroke Grant R01 NS079683 (to M.A.S.) and Grant F30 NS095428 (to C.-J.S.).

  • The online version of this article contains supplemental material.

  • Abbreviations used in this article:

    CIDP
    chronic inflammatory demyelinating polyneuropathy
    MPZ (or P0)
    myelin protein zero
    MS
    multiple sclerosis
    NOD
    nonobese diabetic
    PNS
    peripheral nervous system
    qPCR
    quantitative PCR
    RA
    rheumatoid arthritis
    SAPP
    spontaneous autoimmune peripheral polyneuropathy
    S1P
    sphingosine-1-phosphate
    S1pr1
    sphingosine-1-phosphate receptor 1
    WT
    wild-type.

  • Received September 6, 2017.
  • Accepted December 28, 2017.

References

  1. ↵
    1. Dalakas, M. C.
    2015. Pathogenesis of immune-mediated neuropathies. Biochim. Biophys. Acta - Mol. Basis Dis. 1852: 658–666.
    OpenUrl
  2. ↵
    1. Dalakas, M. C., Medscape
    . 2011. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 7: 507–517.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ropper, A. H.
    2003. Current treatments for CIDP. Neurology 60(8 Suppl. 3): S16–S22.
    OpenUrl
  4. ↵
    1. Kuwabara, S.,
    2. S. Misawa,
    3. M. Mori,
    4. N. Tamura,
    5. M. Kubota,
    6. T. Hattori
    . 2006. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J. Neurol. Neurosurg. Psychiatry 77: 66–70.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Su, M. A.,
    2. D. Davini,
    3. P. Cheng,
    4. K. Giang,
    5. U. Fan,
    6. J. J. DeVoss,
    7. K. P. Johannes,
    8. L. Taylor,
    9. A. K. Shum,
    10. M. Valenzise, et al
    . 2012. Defective autoimmune regulator-dependent central tolerance to myelin protein zero is linked to autoimmune peripheral neuropathy. J. Immunol. 188: 4906–4912.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Meyer zu Horste, G.,
    2. A. K. Mausberg,
    3. S. Cordes,
    4. H. El-Haddad,
    5. H. J. Partke,
    6. V. I. Leussink,
    7. M. Roden,
    8. S. Martin,
    9. L. Steinman,
    10. H. P. Hartung,
    11. B. C. Kieseier
    . 2014. Thymic epithelium determines a spontaneous chronic neuritis in Icam1(tm1Jcgr)NOD mice. J. Immunol. 193: 2678–2690.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Brosnan, J. V.,
    2. R. I. Craggs,
    3. R. H. King,
    4. P. K. Thomas
    . 1987. Reduced susceptibility of T cell-deficient rats to induction of experimental allergic neuritis. J. Neuroimmunol. 14: 267–282.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Salomon, B.,
    2. L. Rhee,
    3. H. Bour-Jordan,
    4. H. Hsin,
    5. A. Montag,
    6. B. Soliven,
    7. J. Arcella,
    8. A. M. Girvin,
    9. J. Padilla,
    10. S. D. Miller,
    11. J. A. Bluestone
    . 2001. Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J. Exp. Med. 194: 677–684.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Abraham, P. M.,
    2. S. H. Quan,
    3. D. Dukala,
    4. B. Soliven
    . 2014. CD19 as a therapeutic target in a spontaneous autoimmune polyneuropathy. Clin. Exp. Immunol. 175: 181–191.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Madia, F.,
    2. G. Frisullo,
    3. V. Nociti,
    4. A. Conte,
    5. M. Luigetti,
    6. A. Del Grande,
    7. A. K. Patanella,
    8. R. Iorio,
    9. P. A. Tonali,
    10. A. P. Batocchi,
    11. M. Sabatelli
    . 2009. pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 14: 107–117.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Csurhes, P. A.,
    2. A. A. Sullivan,
    3. K. Green,
    4. M. P. Pender,
    5. P. A. McCombe
    . 2005. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry 76: 1431–1439.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Beppu, M.,
    2. S. Sawai,
    3. S. Misawa,
    4. K. Sogawa,
    5. M. Mori,
    6. T. Ishige,
    7. M. Satoh,
    8. F. Nomura,
    9. S. Kuwabara
    . 2015. Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 279: 7–10.
    OpenUrl
  13. ↵
    1. Zhang, H. L.,
    2. M. Y. Hassan,
    3. X. Y. Zheng,
    4. S. Azimullah,
    5. H. C. Quezada,
    6. N. Amir,
    7. M. Elwasila,
    8. E. Mix,
    9. A. Adem,
    10. J. Zhu
    . 2012. Attenuated EAN in TNF-α deficient mice is associated with an altered balance of M1/M2 macrophages. PLoS One 7: e38157.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Bour-Jordan, H.,
    2. H. L. Thompson,
    3. J. A. Bluestone
    . 2005. Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J. Immunol. 175: 5649–5655.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Zeng, X. L.,
    2. A. Nagavalli,
    3. C. J. Smith,
    4. J. F. Howard,
    5. M. A. Su
    . 2013. Divergent effects of T cell costimulation and inflammatory cytokine production on autoimmune peripheral neuropathy provoked by Aire deficiency. J. Immunol. 190: 3895–3904.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Sanvito, L.,
    2. A. Makowska,
    3. M. Mahdi-Rogers,
    4. R. D. Hadden,
    5. M. Peakman,
    6. N. Gregson,
    7. R. Nemni,
    8. R. A. Hughes
    . 2009. Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry 80: 333–338.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Moore, K. W.,
    2. R. de Waal Malefyt,
    3. R. L. Coffman,
    4. A. O’Garra
    . 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683–765.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kwilasz, A. J.,
    2. P. M. Grace,
    3. P. Serbedzija,
    4. S. F. Maier,
    5. L. R. Watkins
    . 2015. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology 96(Pt. A): 55–69.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Keravala, A.,
    2. E. R. Lechman,
    3. J. Nash,
    4. Z. Mi,
    5. P. D. Robbins
    . 2006. Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis. Arthritis Res. Ther. 8: R91.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Lubberts, E.,
    2. L. A. Joosten,
    3. L. Van Den Bersselaar,
    4. M. M. Helsen,
    5. A. C. Bakker,
    6. Z. Xing,
    7. C. D. Richards,
    8. W. B. Van Den Berg
    . 2000. Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Clin. Exp. Immunol. 120: 375–383.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Sloane, E.,
    2. A. Ledeboer,
    3. W. Seibert,
    4. B. Coats,
    5. M. van Strien,
    6. S. F. Maier,
    7. K. W. Johnson,
    8. R. Chavez,
    9. L. R. Watkins,
    10. L. Leinwand, et al
    . 2009. Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental multiple sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain Behav. Immun. 23: 92–100.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Cua, D. J.,
    2. B. Hutchins,
    3. D. M. LaFace,
    4. S. A. Stohlman,
    5. R. L. Coffman
    . 2001. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J. Immunol. 166: 602–608.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Go, N. F.,
    2. B. E. Castle,
    3. R. Barrett,
    4. R. Kastelein,
    5. W. Dang,
    6. T. R. Mosmann,
    7. K. W. Moore,
    8. M. Howard
    . 1990. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J. Exp. Med. 172: 1625–1631.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Rousset, F.,
    2. E. Garcia,
    3. T. Defrance,
    4. C. Péronne,
    5. N. Vezzio,
    6. D. H. Hsu,
    7. R. Kastelein,
    8. K. W. Moore,
    9. J. Banchereau
    . 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA 89: 1890–1893.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Joo, H.,
    2. C. Coquery,
    3. Y. Xue,
    4. I. Gayet,
    5. S. R. Dillon,
    6. M. Punaro,
    7. G. Zurawski,
    8. J. Banchereau,
    9. V. Pascual,
    10. S. Oh
    . 2012. Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation. J. Exp. Med. 209: 1335–1348.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Akdis, C. A.,
    2. M. Akdis
    . 2014. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J. Clin. Invest. 124: 4678–4680.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Zhang, H.,
    2. Y. Wang,
    3. E. S. Hwang,
    4. Y. W. He
    . 2016. Interleukin-10: an immune-activating cytokine in cancer immunotherapy. J. Clin. Oncol. 34: 3576–3578.
    OpenUrlFREE Full Text
  28. ↵
    1. Lee, H.,
    2. J. Deng,
    3. M. Kujawski,
    4. C. Yang,
    5. Y. Liu,
    6. A. Herrmann,
    7. M. Kortylewski,
    8. D. Horne,
    9. G. Somlo,
    10. S. Forman, et al
    . 2010. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med. 16: 1421–1428.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Matloubian, M.,
    2. C. G. Lo,
    3. G. Cinamon,
    4. M. J. Lesneski,
    5. Y. Xu,
    6. V. Brinkmann,
    7. M. L. Allende,
    8. R. L. Proia,
    9. J. G. Cyster
    . 2004. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355–360.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Kim, H. J.,
    2. C. G. Jung,
    3. D. Dukala,
    4. H. Bae,
    5. R. Kakazu,
    6. R. Wollmann,
    7. B. Soliven
    . 2009. Fingolimod and related compounds in a spontaneous autoimmune polyneuropathy. J. Neuroimmunol. 214: 93–100.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Su, M. A.,
    2. K. Giang,
    3. K. Žumer,
    4. H. Jiang,
    5. I. Oven,
    6. J. L. Rinn,
    7. J. J. Devoss,
    8. K. P. Johannes,
    9. W. Lu,
    10. J. Gardner, et al
    . 2008. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J. Clin. Invest. 118: 1712–1726.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Shum, A. K.,
    2. J. DeVoss,
    3. C. L. Tan,
    4. Y. Hou,
    5. K. Johannes,
    6. C. S. O’Gorman,
    7. K. D. Jones,
    8. E. B. Sochett,
    9. L. Fong,
    10. M. S. Anderson
    . 2009. Identification of an autoantigen demonstrates a link between interstitial lung disease and a defect in central tolerance. Sci. Transl. Med. 1: 9ra20.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Madsen, K.,
    2. J. Doyle,
    3. M. Tavernini,
    4. R. Fedorak
    . 1999. IL10 colitis scoring Gastroenterology 1999.pdf. 1107–1114.
  34. ↵
    1. Leiter, E. H.
    2001. The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr. Protoc. Immunol. Chapter 15: Unit 15.9.
    OpenUrl
  35. ↵
    1. Xia, R. H.,
    2. N. Yosef,
    3. E. E. Ubogu
    . 2010. Dorsal caudal tail and sciatic motor nerve conduction studies in adult mice: technical aspects and normative data. Muscle Nerve 41: 850–856.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Sensken, S. C.,
    2. M. Nagarajan,
    3. C. Bode,
    4. M. H. Gräler
    . 2011. Local inactivation of sphingosine 1-phosphate in lymph nodes induces lymphopenia. J. Immunol. 186: 3432–3440.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Bouchard, C.,
    2. C. Lacroix,
    3. V. Planté,
    4. D. Adams,
    5. F. Chedru,
    6. J. M. Guglielmi,
    7. G. Said
    . 1999. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52: 498–503.
    OpenUrlCrossRef
    1. Cornblath, D. R.,
    2. D. E. Griffin,
    3. D. Welch,
    4. J. W. Griffin,
    5. J. C. McArthur
    . 1990. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies. J. Neuroimmunol. 26: 113–118.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Schmidt, B.,
    2. K. V. Toyka,
    3. R. Kiefer,
    4. J. Full,
    5. H. P. Hartung,
    6. J. Pollard
    . 1996. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19: 474–487.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Serreze, D. V.,
    2. H. D. Chapman,
    3. C. M. Post,
    4. E. A. Johnson,
    5. W. L. Suarez-Pinzon,
    6. A. Rabinovitch
    . 2001. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J. Immunol. 166: 1352–1359.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Kühn, R.,
    2. J. Löhler,
    3. D. Rennick,
    4. K. Rajewsky,
    5. W. Müller
    . 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263–274.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Sellon, R. K.,
    2. S. Tonkonogy,
    3. M. Schultz,
    4. L. A. Dieleman,
    5. W. Grenther,
    6. E. Balish,
    7. D. M. Rennick,
    8. R. B. Sartor
    . 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 66: 5224–5231.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Asghar, M. N.,
    2. R. Emani,
    3. C. Alam,
    4. T. O. Helenius,
    5. T. J. Grönroos,
    6. O. Sareila,
    7. M. U. Din,
    8. R. Holmdahl,
    9. A. Hänninen,
    10. D. M. Toivola
    . 2014. In vivo imaging of reactive oxygen and nitrogen species in murine colitis. Inflamm. Bowel Dis. 20: 1435–1447.
    OpenUrl
  44. ↵
    1. Blunt, T.,
    2. N. J. Finnie,
    3. G. E. Taccioli,
    4. G. C. Smith,
    5. J. Demengeot,
    6. T. M. Gottlieb,
    7. R. Mizuta,
    8. A. J. Varghese,
    9. F. W. Alt,
    10. P. A. Jeggo,
    11. S. P. Jackson
    . 1995. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell 80: 813–823.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Serreze, D. V.,
    2. H. D. Chapman,
    3. D. S. Varnum,
    4. M. S. Hanson,
    5. P. C. Reifsnyder,
    6. S. D. Richard,
    7. S. A. Fleming,
    8. E. H. Leiter,
    9. L. D. Shultz
    . 1996. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig mu null mice. J. Exp. Med. 184: 2049–2053.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Groux, H.,
    2. A. O’Garra,
    3. M. Bigler,
    4. M. Rouleau,
    5. S. Antonenko,
    6. J. E. de Vries,
    7. M. G. Roncarolo
    . 1997. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389: 737–742.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Green, D. S.,
    2. D. M. Center,
    3. W. W. Cruikshank
    . 2009. Human immunodeficiency virus type 1 gp120 reprogramming of CD4+ T-cell migration provides a mechanism for lymphadenopathy. J. Virol. 83: 5765–5772.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Cyster, J. G.,
    2. S. R. Schwab
    . 2012. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30: 69–94.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Jerez, A.,
    2. M. J. Clemente,
    3. H. Makishima,
    4. H. Koskela,
    5. F. Leblanc,
    6. K. Peng Ng,
    7. T. Olson,
    8. B. Przychodzen,
    9. M. Afable,
    10. I. Gomez-Segui, et al
    . 2012. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120: 3048–3057.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Mao-Draayer, Y.,
    2. J. Sarazin,
    3. D. Fox,
    4. E. Schiopu
    . 2017. The sphingosine-1-phosphate receptor: a novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin. Immunol. 175: 10–15.
    OpenUrl
  51. ↵
    1. Calabresi, P. A.,
    2. E. W. Radue,
    3. D. Goodin,
    4. D. Jeffery,
    5. K. W. Rammohan,
    6. A. T. Reder,
    7. T. Vollmer,
    8. M. A. Agius,
    9. L. Kappos,
    10. T. Stites, et al
    . 2014. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 13: 545–556.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Mandala, S.,
    2. R. Hajdu,
    3. J. Bergstrom,
    4. E. Quackenbush,
    5. J. Xie,
    6. J. Milligan,
    7. R. Thornton,
    8. G. J. Shei,
    9. D. Card,
    10. C. Keohane, et al
    . 2002. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346–349.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Mirakian, R.,
    2. L. J. Hammond,
    3. G. F. Bottazzo
    . 2001. TH1 and TH2 cytokine control of thyrocyte survival in thyroid autoimmunity. Nat. Immunol. 2: 371.
    OpenUrlPubMed
    1. Lopatin, U.,
    2. X. Yao,
    3. R. K. Williams,
    4. J. J. Bleesing,
    5. J. K. Dale,
    6. D. Wong,
    7. J. Teruya-Feldstein,
    8. S. Fritz,
    9. M. R. Morrow,
    10. I. Fuss, et al
    . 2001. Increases in circulating and lymphoid tissue interleukin-10 in autoimmune lymphoproliferative syndrome are associated with disease expression. Blood 97: 3161–3170.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Lalani, I.,
    2. K. Bhol,
    3. A. R. Ahmed
    . 1997. Interleukin-10: biology, role in inflammation and autoimmunity. [Published erratum appears in 1998 Ann. Allergy Asthma Immunol. 80: A–6.] Ann. Allergy Asthma Immunol. 79: 469–483.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Quan, S.,
    2. H. J. Kim,
    3. D. Dukala,
    4. J. R. Sheng,
    5. B. Soliven
    . 2015. Impaired dendritic cell function in a spontaneous autoimmune polyneuropathy. J. Immunol. 194: 4175–4184.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Kanda, T.,
    2. Y. Numata,
    3. H. Mizusawa
    . 2004. Chronic inflammatory demyelinating polyneuropathy: decreased claudin-5 and relocated ZO-1. J. Neurol. Neurosurg. Psychiatry 75: 765–769.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Neyt, K.,
    2. F. Perros,
    3. C. H. GeurtsvanKessel,
    4. H. Hammad,
    5. B. N. Lambrecht
    . 2012. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 33: 297–305.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Valenzise, M.,
    2. T. Aversa,
    3. G. Salzano,
    4. G. Zirilli,
    5. F. De Luca,
    6. M. Su
    . 2017. Novel insight into chronic inflammatory demyelinating polineuropathy in APECED syndrome: molecular mechanisms and clinical implications in children. Ital. J. Pediatr. 43: 11.
    OpenUrl
  60. ↵
    1. Louvet, C.,
    2. B. G. Kabre,
    3. D. W. Davini,
    4. N. Martinier,
    5. M. A. Su,
    6. J. J. DeVoss,
    7. W. L. Rosenthal,
    8. M. S. Anderson,
    9. H. Bour-Jordan,
    10. J. A. Bluestone
    . 2009. A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J. Exp. Med. 206: 507–514.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Briet, C.,
    2. G. Bourdenet,
    3. U. C. Rogner,
    4. C. Becourt,
    5. I. Tardivel,
    6. L. Drouot,
    7. C. Arnoult,
    8. J. C. do Rego,
    9. N. Prevot,
    10. C. Massaad, et al
    . 2017. The spontaneous autoimmune neuromyopathy in ICOSL-/- NOD mice is CD4+ T-cell and interferon-γ dependent. Front. Immunol. 8: 287.
    OpenUrl
  62. ↵
    1. Arnon, T. I.,
    2. Y. Xu,
    3. C. Lo,
    4. T. Pham,
    5. J. An,
    6. S. Coughlin,
    7. G. W. Dorn,
    8. J. G. Cyster
    . 2011. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333: 1898–1903.
    OpenUrlAbstract/FREE Full Text
    1. Bankovich, A. J.,
    2. L. R. Shiow,
    3. J. G. Cyster
    . 2010. CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4. J. Biol. Chem. 285: 22328–22337.
    OpenUrlAbstract/FREE Full Text
    1. Shiow, L. R.,
    2. D. B. Rosen,
    3. N. Brdicková,
    4. Y. Xu,
    5. J. An,
    6. L. L. Lanier,
    7. J. G. Cyster,
    8. M. Matloubian
    . 2006. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440: 540–544.
    OpenUrlCrossRefPubMed
    1. Willinger, T.,
    2. S. M. Ferguson,
    3. J. P. Pereira,
    4. P. De Camilli,
    5. R. A. Flavell
    . 2014. Dynamin 2-dependent endocytosis is required for sustained S1PR1 signaling. J. Exp. Med. 211: 685–700.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Xin, Q.,
    2. J. Li,
    3. J. Dang,
    4. X. Bian,
    5. S. Shan,
    6. J. Yuan,
    7. Y. Qian,
    8. Z. Liu,
    9. G. Liu,
    10. Q. Yuan, et al
    . 2015. miR-155 deficiency ameliorates autoimmune inflammation of systemic lupus erythematosus by targeting S1pr1 in Faslpr/lpr mice. J. Immunol. 194: 5437–5445.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Igarashi, J.,
    2. P. A. Erwin,
    3. A. P. Dantas,
    4. H. Chen,
    5. T. Michel
    . 2003. VEGF induces S1P1 receptors in endothelial cells: implications for cross-talk between sphingolipid and growth factor receptors. Proc. Natl. Acad. Sci. USA 100: 10664–10669.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Carlson, C. M.,
    2. B. T. Endrizzi,
    3. J. Wu,
    4. X. Ding,
    5. M. A. Weinreich,
    6. E. R. Walsh,
    7. M. A. Wani,
    8. J. B. Lingrel,
    9. K. A. Hogquist,
    10. S. C. Jameson
    . 2006. Kruppel-like factor 2 regulates thymocyte and T-cell migration. Nature 442: 299–302.
    OpenUrlCrossRefPubMed
  69. ↵
    1. Asadullah, K.,
    2. W. Sterry,
    3. H. D. Volk
    . 2003. Interleukin-10 therapy--review of a new approach. Pharmacol. Rev. 55: 241–269.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Hughes, R. A. C.,
    2. M. Dalakas,
    3. N. Latov,
    4. J.-M. Léger,
    5. I. S. J. Merkies,
    6. E. Nobile-Orazio,
    7. C. Agoropoulou,
    8. D. A. Häring,
    9. L. Zhang-Auberson,
    10. P. Von Rosenstiel,
    11. H. P. Hartung
    . 2013. Oral fingolimod (FTY720) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): Study design of the phase 3 forcidp trial. J. Peripher. Nerv. Syst. 18: S48–S49.
    OpenUrl
  71. ↵
    1. Zimmer, L.,
    2. S. M. Goldinger,
    3. L. Hofmann,
    4. C. Loquai,
    5. S. Ugurel,
    6. I. Thomas,
    7. M. I. Schmidgen,
    8. R. Gutzmer,
    9. J. S. Utikal,
    10. D. Göppner, et al
    . 2016. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur. J. Cancer 60: 210–225.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Kourie, H. R.,
    2. J. A. Klastersky
    . 2016. Side-effects of checkpoint inhibitor-based combination therapy. Curr. Opin. Oncol. 28: 306–313.
    OpenUrl
  73. ↵
    1. Parra, B.,
    2. J. Lizarazo,
    3. J. A. Jiménez-Arango,
    4. A. F. Zea-Vera,
    5. G. González-Manrique,
    6. J. Vargas,
    7. J. A. Angarita,
    8. G. Zuñiga,
    9. R. Lopez-Gonzalez,
    10. C. L. Beltran, et al
    . 2016. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375: 1513–1523.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Cao-lormeau, V. M.,
    2. A. Blake,
    3. S. Mons,
    4. S. Lastere,
    5. C. Roche,
    6. J. Vanhomwegen,
    7. T. Dub,
    8. L. Baudouin,
    9. A. Teissier,
    10. P. Larre, et al
    . 2016. Guillain-Barré syndrome outbreak caused by ZIKA virus infection in French Polynesia. Lancet 387: 1531–1539.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section